Prof Tom John· @TommyJohn00 · X·· 13 小时前评分70
正文 · 机器翻译
恭喜 @sands_jacob 精彩展示了 Dephi-305。成果令人印象深刻，赢得了当之无愧的起立鼓掌。#LCSM #ESMO26
加入 Tarlatamab 后，OS 显著改善。AEs 有所增加，但符合预期，且不算严重。新的 SoC。
84 浏览 · 5 赞 · 2 转发 · 0 回复
会议摘要
3821P按 SCLC 对上
Sustained survival with extended follow-up of tarlatamab plus anti-PD-L1 as first-line maintenance (1LM) after chemoimmunotherapy for extensive-stage small cell lung cancer (ES-SCLC): DeLLphi-303 phase 1b study
https://esmocongress.esmo.org3848P按 SCLC 对上
Cytokine release syndrome in patients receiving tarlatamab for extensive-stage small cell lung cancer: A real-world analysis
https://esmocongress.esmo.orgLBA3按 Presidential Symposium I 对上
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org来源：Prof Tom John · x.com